DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
Key Highlights
- ➤DataMEDS amends LOI with Datavault AI, DHP, EOS, Scilex and HealthBridge Advisors
- ➤Transaction would acquire QOLPOM delivery and wearable biometric intellectual property
- ➤DataMEDS would license Datavault AI healthcare intellectual property and DHP outcomes technology
- ➤DataMEDS seeks controlling interest in Tollo Health and Health Lives Here app
- ➤Transaction targets Q4 2026 closing, subject to definitive agreements and due diligence
Expert Statements
Paul Arena, CEO of Data Health Partners
“With the recent finalization of FDA guidance as it relates to prescription drug apps and software, we are excited to become shareholders of DataMEDS now that it has a clear regulatory framework to optimize its Health Lives Here mobile application to be patients' behavior-change ally, leveraging the key intellectual property being brought in-house through this transaction.”
Paul Arena, CEO of Data Health Partners
“Given the proprietary position gained via DataMEDS' recent exclusive license from DHP's subsidiary REBOOT to patents and patent applications enabling GLP-1 receptor agonist drug-focused behavioral health technologies, we believe this new proposed transaction would further strengthen DataMEDS' position towards the center of the patient-focused healthcare mobile app and software universe.”
Paul Arena, CEO of Data Health Partners
“With the advent of autonomous aerial drones able to deliver medical products, DataMEDS is preparing for the coming changes in healthcare delivery.”
Paul Arena, CEO of Data Health Partners
“Integrating the QOLPOM biometric verification and automated delivery patents with the DataMEDS artificial intelligence and blockchain platforms supports secure, personalized medication fulfillment and could generate de-identified real-world evidence on patient outcomes, with patient consent, that may be valuable to healthcare stakeholders, including pharmaceutical manufacturers.”
Nathaniel Bradley, CEO of Datavault AI and EOS
“DataMEDS will reduce the cost, improve the quality of care and empower patients with meaningful data driven outcomes.”
Nathaniel Bradley, CEO of Datavault AI and EOS
“This is an enduring vision of true pioneers in behavioral healthcare.”
Nathaniel Bradley, CEO of Datavault AI and EOS
“DataMEDS is seeking to operationalize Datavault AI's potential in healthcare.”
Nathaniel Bradley, CEO of Datavault AI and EOS
“Datavault AI is excited to be able to meaningfully participate in the value creation at MEDS via equity participation and royalties for the use of our technologies.”
Nathaniel Bradley, CEO of Datavault AI and EOS
“Given the significant amount of due diligence and document preparation that has already taken place under the previous LOI, we are targeting a fourth quarter 2026 closing.”
Nathaniel Bradley, CEO of Datavault AI and EOS
“We look forward to supporting DataMEDS as it seeks to disrupt healthcare via its ability to create good health outcomes through a vertically integrated physical, digital and intellectual property healthcare delivery stack.”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“With the recent launch of the Health Lives Here app together with Tollo Health and NFL Alumni Health, we are beginning to see patients better understand our vision for the future of health, where they can set goals and work toward them using the physical and digital healthcare infrastructure being assembled within DataMEDS.”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“Adding Data Health Partners' patented technology for patient goal setting, progression and achievement, alongside our DelivMeds intellectual property and the QOLPOM biometric verification and delivery patents, positions DataMEDS to enable key aspects of healthcare delivery through telemedicine.”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“We believe that our physical infrastructure, which includes a pharmacy, a pharmaceutical distribution center and a diagnostic laboratory, combined with our Health Lives Here telemedicine and wellness offering, DelivMeds, our EinsteinRx™-driven pharmacy hub and our intellectual property, has the potential to disrupt the digital healthcare market in the United States.”
TAMPA, FL / ACCESS Newswire / October 22, 2026 / DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx(™) artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has entered into an amended and restated non-binding letter of intent dated October 19, 2026 ("LOI") with Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") (NASDAQ:SCLX) and HealthBridge Advisors, LLC ("HealthBridge Advisors"). EOS and Scilex each own a portion of the Quality of Life Peace of Mind (QOLPOM) intellectual property portfolio that is expected to be reunited through this transaction. DataMEDS' subsidiary Corexa Health has an established distribution nationwide network of 6,500 independent pharmacies.
Get started
Create a free account to read the full story.